Tongling Jieya Biologic Technology Co., Ltd.

SZSE:301108 Stock Report

Market Cap: CN¥2.2b

Tongling Jieya Biologic Technology Future Growth

Future criteria checks 5/6

Tongling Jieya Biologic Technology is forecast to grow earnings and revenue by 55.4% and 23.7% per annum respectively.

Key information

55.4%

Earnings growth rate

n/a

EPS growth rate

Personal Products earnings growth25.6%
Revenue growth rate23.7%
Future return on equityn/a
Analyst coverage

Low

Last updated31 Oct 2024

Recent future growth updates

Recent updates

Be Wary Of Tongling Jieya Biologic Technology (SZSE:301108) And Its Returns On Capital

Sep 28
Be Wary Of Tongling Jieya Biologic Technology (SZSE:301108) And Its Returns On Capital

Earnings and Revenue Growth Forecasts

SZSE:301108 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2025825157N/A1961
12/31/2024720134N/A1761
9/30/202458356-1778N/A
6/30/202462877-22121N/A
3/31/202462492-2588N/A
12/31/2023623115-284N/A
9/30/202358810664139N/A
6/30/2023587117169206N/A
3/31/2023614131158185N/A
1/1/2023667141269299N/A
9/30/2022696164232265N/A
6/30/2022717172204238N/A
3/31/2022818185291332N/A
1/1/2022984220128200N/A
9/30/20211,024243187285N/A
6/30/20211,103252179298N/A
3/31/202195622969195N/A
12/31/202074318084188N/A
12/31/20193076878107N/A
12/31/2018312582737N/A
12/31/201724326N/A35N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 301108's forecast earnings growth (55.4% per year) is above the savings rate (2.8%).

Earnings vs Market: 301108's earnings (55.4% per year) are forecast to grow faster than the CN market (26.3% per year).

High Growth Earnings: 301108's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 301108's revenue (23.7% per year) is forecast to grow faster than the CN market (13.9% per year).

High Growth Revenue: 301108's revenue (23.7% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 301108's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y